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Purpose/Objective: SBRT aims to deliver high doses in few fractions, 
thus requiring high confidence in accuracy of the treatment planning 
and delivery process. Being one source of uncertainty, respiratory 
motion is usually accounted for by 4DCT imaging and deriving the 
internal target volume (ITV) as basis of the PTV definition. In doing so, 
variations of breathing patterns and motion-related underestimation 
of normal tissue dose are not considered. In this study, dose 
accumulation methods are proposed, incorporated into DVH 
computation, and applied for DVH analyses for SBRT plans of liver and 
lung lesions. 
Materials and Methods: The study is based on liver and lung SBRT 
plans of 6 patients [5 fractions; 56 Gy to ITV; ITV derived from 10-
phase 4DCT; PTV = ITV + 4 mm margin; dose delivery by Varian VMAT]. 
Two approaches are followed for the analysis of respiratory motion 
effects. First, the planning CT (average CT of the 4DCT) and the 
breathing phases of the 4DCT are non-linearly registered. The 
resulting vector fields are applied for deforming the planned dose 
distribution; the altered doses are accumulated and the resulting 
DVHs evaluated (DVHacc). For the second approach, breath curves 
measured during 4DCT data acquisition (Siemens Somatom with Anzai 
belt) are analyzed wrt. patient-specific variations in breath 
amplitude. A regression is performed between the registration vector 
fields and the corresponding values from the breath curve. The linear 
model is then used to scale the original vector fields acc. to the 
breath curve analysis results, and the scaled fields are applied for 
dose accumulation and DVH analysis (DVHscaled). DVHacc and DVHscaled 
analysis results are compared to corresponding values for the 
originally planned dose distribution and DVHs (DVHorig). 
Results: The breath curves mainly reflect regular breathing patterns. 
The DVH analyses primarily illustrate motion-related dose blurring 
effects: maximum GTV point doses seen in DVHorig are smoothed out in 
DVHacc and DVHscaled. As expected, the minimum GTV point dose also 
decrease when analyzing DVHscaled (up to >4 Gy compared to DVHorig). 
However, minimum GTV point doses are not observed to fall below 
the prescribed dose in either DVHacc or especially DVHscaled. Further, 
DVH-related measures for normal tissue exposure are only marginally 
affected. For example, V20Gy (lungs) and V30Gy (liver) of DVHorig, 
DVHacc,and DVHscaled correspond within 1-2 volume percentage for all 
plans. 
Conclusions: Accounting for respiratory motion during SBRT treatment 
planning offers higher confidence in the accuracy of especially the 
treatment planning process, but still remains challenging. For the 
present patients and the proposed dose accumulation methods, 
motion-related changes of DVH measures were clinically acceptable. 
However, additional uncertainties like interplay effects (due to the 
IMRT character of VMAT) still need to be considered.  
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Purpose/Objective: The 2D-bMLC concept aims to provide quick 
aperture modulation. We therefore developed a treatment planning 
system (TPS) for ultra-fast rotational IMRT with the 2D-bMLC. For 
dosimetric evaluation patient plans with delivery times of 20-60s per 
fraction were optimized and compared to standard step and shot IMRT 
plans. 
Materials and Methods: The 2D-bMLC consists of individually 
controlled absorbers arranged side by side forming a 2d aperture. The 
design, which leads to radiation fields fragmented into stripes (fig a), 
aims at aperture changes below 100 ms. Within the TPS a treatment 
machine with a FFF 7MV linac source, a 2D-bMLC, a max dose rate of 
2000 MU/min and a SAD of 800 mm was modeled. The total fraction 
dose is delivered in one gantry rotation with constant speed. 
Treatment plans are generated for a predefined delivery time TF (fig 
b). The TPS uses a PB dose algorithm and the 48 arc segments are 
approx. by fixed beam directions. For a prostate patient (patient I) 
median doses of 76 Gy and 70 Gy in 35 fraction were prescribed to the 
GTV and the PTV respectively. For the rectum a dose constraint of 
D50% < 40 Gy was used. For Patient II with a nasopharyngeal carcinoma 
54 Gy in 30 fractions were prescribed to the PTV and 66 Gy to the 
boost region. Constraints for the spinal cord were D1% < 40 Gy, for the 
parotids D50% < 30 Gy; Dmean < 26 Gy. For both patients, plans with TF of 
20s (plan P20), 30s (P30) and 60s (P60) were generated and compared 
to clinically accepted 9-field IMRT plans. D99%, D50%, D1%, Dmean, 95% 
coverage and inhomogeneity (TDI) for the targets as well as the mean 
dose to the normal tissue, excluding the PTV, were calculated.  An 
additional tool was developed to compute the 2D-bMLC plans with a 
MC (Geant4.9.5) method, including a realistic model of the collimator 
absorber and gantry dynamic. 
 
  
Results: All 2D-bMLC plans calculated with the TPS fulfill the clinical 
goals. In the table (fig c), dose parameters are shown for patient I. 
Concerning the coverage and the TDI, the plans are in good agreement 
with the IMRT plan. Relative differences are below 1% while D50% to 
the rectum was decreased with P60 and P30. For patient II, coverage 
of the boost region is reduced by ~1% while PTV coverage is improved 
from 91.0% (IMRT) to 97.2% (P60), 96.7% (P30), 94.7% (P20). TDI for 
the boost region is similar for all plans. D1% to the spinal cord and D50% 
and Dmean to the parotids are slightly decreased (diff. < 3 Gy). Dmean to 
the normal tissue is decreased by > 10%. Compared to the TPS 
calculations the MC computed plans show increased values of D50% and 
D1% for the targets as well as increased TDI. P30 and P20 might need 
rescaling to assure adequate target coverage. Also Dmean to the normal 
tissue is increased in the MC plans. 
Conclusions: The 2D-bMLC plans fulfill the clinical goals and the 
relevant dosimetric parameters are comparable to the IMRT plans; 
Sparing of OARs is slightly improved. The 4D-MC tool allows to 
recompute the plans including the full dynamic of the delivery 
machine. 
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Purpose/Objective: The Papillon P50 (Ariane Medical Systems, Derby, 
UK) is a relatively new radiotherapy treatment machine delivering low 
energy x-rays (50 kV generating potential) for contact radiotherapy 
and IORT (Intra-Operative Radiotherapy). In contact radiotherapy the 
end of the treatment machine is brought into contact with the 
tumour. The size of the field is small (<= 3 cm dia.) and the distance 
from the source to the tumour is very short (≈3-4 cm). In this study a 
Monte Carlo simulation of the Papillon P50 is created to verify that 
the parameters in the UK Dosimetry Code of Practice (Klevenhagen et 
al. 1996, Phys. Med. Biol. 41, 2605) are applicable to this new regime: 
specifically backscatter factor, chamber factor and mass energy-
absorption coefficient ratio. These values are currently extrapolated 
due to the short SSD and small field size.  
Materials and Methods: Geant 4 was used to construct a virtual 
representation of the Papillon P50 geometry. The beam spectrum of 
the Papillon P50 was simulated by creating a 50 keV electron beam 
 
S168  2nd ESTRO Forum 2013	
which was incident upon the target. The resulting bremsstrahlung x-
ray beam was then propagated through the simulated machine and 
into a phantom. A scoring plane at the surface of the phantom was 
used to compute the backscatter factor (Bw) and the mass-energy 
absorption coefficient ratio [(μen/ρ)w/air]air. The chamber factor (kch) 
was also measured experimentally by comparing the chamber reading 
with the dose obtained using the backscatter-factor method. 
Results: The HVL was calculated to be 0.9 mm Al similar to the 
experimental value of 0.77 mm Al. Simulated PDD curves agreed well 
with previous measurements. The mass-energy absorption coefficient 
for water to air at the surface of a water phantom was found to be 
1.023 + 0.001 consistent with the value in the current UK code of 
practice for the same quality index. The backscatter factor was 
estimated to be 1.05 + 0.005 for an 11 mm field radius as shown by 
Figure 1. This reduces the value of a dose measurement by 
approximately 1% relative to the current UK code of practice value 
based on published studies. The value of the chamber correction 
factor kch obtained through measurement using low and very low 
energy codes was 1.04 + 0.01, lower than the 1.06 currently in the 
code of practice but within the uncertainties in the original studies. 
 
 
Conclusions: The values for the calibration coefficients generated in 
this study are close to those in the UK code of practice. A difference 
of 2% was found for the chamber factor but this coefficient is known 
to be subject to large uncertainties of which the code of practice 
gives a representative value. Work is continuing to model the 
PTW23342 ionisation chamber and produce a chamber factor via 
Monte Carlo simulation. Initial results are higher than experimental 
values. 
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Purpose/Objective: For the TrueBeamTM linac, the vendors (Varian 
Medical Systems) only include detailed information on the components 
from the secondary collimators and downstreams in their Monte Carlo 
data package. In order to describe the upper part of the TrueBeam 
linac the vendor supply phase space files (PSF). This leads to 
consequences for the user; it is no longer possible to commission the 
Monte Carlo (MC) model against a specific linac. Moreover, the 
number of unique particles is limited by the size of the PSF, thereby 
limiting the achievable accuracy in dose calculations. The term 'latent 
variance' was coined by Sempau et al. (2001) and refers to the limit on 
the achievable total variance as a consequence of the number of 
particles in the PSF being finite. The purpose of this study was to 
determine the latent standard deviation of the vendor supplied 
TrueBeam PSFs for a clinically relevant situation  
Materials and Methods: The total variance of a patient and/or 
phantom simulation is a combination of the latent variance of the PSF, 
A, and the statistical variance of the dose scoring simulation, B. 
  
where N is the number of simulated histories.  
By employing a K-fold recycling of the PSF particles equation 1 can be 
rewritten as 
 
 The total variance can be represented as a function of K-1 and fitted 
to a straight line. The latent variance of the PSF is given by the 
crossing of this line with the axis K-1=0.  
The most recent TrueBeam PSFs were downloaded from 
myVarian.com. A 10×10 cm2 field was simulated in BEAMnrc using 
combined and trigometrically 'flattened' PSFs for each energy and 
fluence mode as input. No variance reductions were employed and 
PSFs were scored at 90 cm SSD. 
DOSXYZnrc was employed to score dose in a 40×40×40 cm3 
homogeneous water phantom using the 10×10 cm2 field PSFs as input 
directly on the phantom surface. The voxel size was 0.25×0.25×0.25 
cm3 and the variance in the 27 voxels located around the beam 
isocenter was scored.  
Results: The total variance, q, as a function of the inverse recycling 
rate, K-1, is shown in figure 1. The latent SD for each energy and mode 
is shown in table 1. 
 
  
Table 1. Absolute and relative latent standard deviation for each 
energy and mode studied. The relative latent standard deviation is 
given with respect to the dose of the isocenter voxel. 
Nominal 
Energy 
(MeV) 
Mode Latent SD 
(eV cm2 g-1 per 
history) 
Relative Latent 
SD  
(%) 
6 Flattened 6.13±0.46 1.02±0.08 
6 FFF 13.07±0.98 0.85±0.14 
10 Flattened 12.04±1.94 0.74±0.06 
10 FFF 26.45±1.58 0.41±0.02 
 
Conclusions: The latent SDs of the vendor supplied TrueBeam PSFs 
were determined for a clinically relevant situation. The latent SD is 
most likely sufficiently low for many applications (e.g. MC based 
patient specific QA), but inadequate if the goal is to perform 
simulations requiring a high level of accuracy (e.g.computation of 
correction factors). MC is often considered the golden standard in 
comparison of dose calculation algorithms. Regardless of the level of 
the latent SD, such studies would be biased as other algorithms 
typically are based on dose measurements for a specific linac, 
whereas the PSFs are generic.  
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Purpose/Objective: In proton therapy, complex density 
heterogeneities within the beam path pose a challenge to analytical 
dose calculation algorithms so that the reliability of the predicted 
dose distributions might be questioned. For these cases in which 
substantial dose errors are expected, resorting to more accurate 
Monte Carlo (MC) simulations might be essential to ensure a successful 
treatment outcome and therefore the benefit is worth a presumably 
long computation time. The aim of this study was to obtain a 
geometrical indicator for the accuracy of dose delivery based on 
analytical dose calculations for proton therapy fields. 
